Resolution Biomedical

Executive Summary

Resolution Biomedical (RBI) is a privately-held medical device and diagnostics company based in San Diego, California, founded in 2009. The company initially focused on developing the ClearPrep liquid-based cytology system, designed to improve cellular sample collection and analysis. Over time, RBI expanded its product portfolio to include sample collection and transport products, notably validated transport tubes for COVID-19 PCR testing, which became a significant revenue driver during the pandemic. Despite its early innovation in cytology and successful pivot to COVID-19 diagnostics, RBI remains a small, privately-held entity with limited public disclosures on financials, stage, or recent developments. The company operates in the competitive diagnostics and medical device sectors, with potential applications in oncology screening but faces challenges from larger, well-funded competitors and evolving market demands.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for next-generation ClearPrep system40% success
• Q2 2027Strategic partnership with major diagnostics lab for cervical cancer screening30% success
• TBDExpansion into point-of-care diagnostics via new transport media product25% success